Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on October 24, 2023. The registrant is a Delaware corporation with principal executive offices in Waltham, Massachusetts, and its common stock trades on the Nasdaq Capital Market under the symbol AGLE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific disclosure event and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is the release of an updated corporate presentation on the Company's website. This presentation includes non-clinical updates for the anti-TL1A antibody research program, SPY002, demonstrating monomer and trimer binding at picomolar potencies.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard regulatory disclaimer. The information provided in the attached presentation is furnished pursuant to Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc. (AGLE), not Spyre Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Corporate Presentation) for detailed non-clinical data on the SPY002 program.
- Confirm that the disclosed data represents pre-clinical findings (binding potencies) rather than clinical trial results.
- Note that the presentation content is not legally "filed" and carries different liability standards than formal SEC filings.